Meeting News CoverageVideo

Real-world experience with 3-D regimen lives up to phase 3 studies

BARCELONA — In this video perspective from the International Liver Congress 2016, Heiner Wedemeyer, MD, research group leader, department of gastroenterology, hepatology and endocrinology at Hannover Medical School in Germany, discusses his real-world experience with the German Hepatitis C-Registry. Specifically, Wedemeyer looked at the impact of Viekirax (ombitasvir/parataprevir/ritonavir, AbbVie) and Exviera (dasabuvir, AbbVie), together known as Viekira Pak in the United States, in his own practice, showing that the everyday impact is similar to that seen in phase 3 trials.

“In Germany, we have many patients with genotype 1b infection and basically in my practice we have cured all 1b patients with this regimen,” Wedemeyer told HCV Next. “We do not need ribavirin and this regimen works without ribavirin in patients with compensated liver cirrhosis, which was for us very important.”

In his study, Wedemeyer showed 96% of patients with genotype 1 (n = 486 of 505) and 100% (n = 53) of patients with genotype 4 HCV achieved sustained virologic response at 12 weeks after treatment. Of the 1,017 patients who initiated treatment, the registry data showed a 1.5% discontinuation due to common adverse events with severe adverse events reported in only 1% treated without ribavirin and 3% in those treated with ribavirin. This study is ongoing, according to a press release.

Disclosure: Wedemeyer reports various financial relationships with Abbott, AbbVie, Achillion Boehringer Ingelheim, Bristol-Meyers Squibb, Gilead, GlaxoSmithKline, ITS, Janssen, Merck Sharp & Dohme, Novartis, Roche, Siemens and Transgene.

BARCELONA — In this video perspective from the International Liver Congress 2016, Heiner Wedemeyer, MD, research group leader, department of gastroenterology, hepatology and endocrinology at Hannover Medical School in Germany, discusses his real-world experience with the German Hepatitis C-Registry. Specifically, Wedemeyer looked at the impact of Viekirax (ombitasvir/parataprevir/ritonavir, AbbVie) and Exviera (dasabuvir, AbbVie), together known as Viekira Pak in the United States, in his own practice, showing that the everyday impact is similar to that seen in phase 3 trials.

“In Germany, we have many patients with genotype 1b infection and basically in my practice we have cured all 1b patients with this regimen,” Wedemeyer told HCV Next. “We do not need ribavirin and this regimen works without ribavirin in patients with compensated liver cirrhosis, which was for us very important.”

In his study, Wedemeyer showed 96% of patients with genotype 1 (n = 486 of 505) and 100% (n = 53) of patients with genotype 4 HCV achieved sustained virologic response at 12 weeks after treatment. Of the 1,017 patients who initiated treatment, the registry data showed a 1.5% discontinuation due to common adverse events with severe adverse events reported in only 1% treated without ribavirin and 3% in those treated with ribavirin. This study is ongoing, according to a press release.

Disclosure: Wedemeyer reports various financial relationships with Abbott, AbbVie, Achillion Boehringer Ingelheim, Bristol-Meyers Squibb, Gilead, GlaxoSmithKline, ITS, Janssen, Merck Sharp & Dohme, Novartis, Roche, Siemens and Transgene.

    See more from International Liver Congress